The knowledge of which size of aggregates is responsible for seeding and which antibodies better recognize these forms of Tau can have an impact in how antibodies are selected for therapy, not only for AD but also for other tauopathies, such as Progressive supranuclear palsy, corticobasal degeneration or frontotemporal dementia. The gene discussed is MAPT; the disease is corticobasal degeneration disorder.